

Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023

- *Sensorion to host a webconference dedicated to shareholders on September 25th, 2023, in French, at 6am ET (12pm CET)*

Montpellier, September 21, 2023, 7.30am CET – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, is pleased to announce it is hosting a webconference on September 25, 2023, and its participation in two upcoming investor conferences in October 2023.

Sensorion's CEO, Nawal Ouzren, and management team will host a **webconference dedicated to shareholders**, in French, on September 25, 2023, at 6am ET (12pm CET), to comment on the Company's latest activities and outlook.

[Click here to join the meeting](#)

Meeting ID: 377 992 162 784

Secret code: gtEzYU

You will also be able to join the webconference from [Sensorion's website](#).

Nawal Ouzren will attend, in-person, **Chardan's 7th Annual Genetic Medicines Conference**, held on October 2-3, 2023, in New-York City, USA. On that occasion, Nawal will participate in a fireside chat with analyst Geulah Livshits on October 3, 2023, at 8am ET. Sensorion's CEO will also be available for one-on-one meetings throughout the conference.

Nawal Ouzren will participate, in-person, in the **HealthTech Innovation Days (HTID)** that will take place on October 24-25, 2023, in Paris, France. Nawal will be available for one-on-one meetings throughout the conference.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. OTOF-GT targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in *GJB2* gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion's portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders.

Sensorion's clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

www.sensorion.com

Press release

Contacts

Investor Relations

Noémie Djokovic, Investor Relations and
Communication Associate
ir.contact@sensorion-pharma.com

Press Relations

Ulysse Communication
Pierre-Louis Germain / 00 33 (0)6 64 79 97 51
plgermain@ulyse-communication.com

Bruno Arabian / 00 00(0)6 87 88 47 26
barabian@ulyse-communication.com

Label: **SENSORION**
ISIN: **FR0012596468**
Mnemonic: **ALSEN**



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2022 full year financial report published on March 30, 2023, and available on our website and to the development of economic conditions, financial markets, and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.